NDA 050796 · B Braun
Ceftriaxone and Dextrose In Duplex Container
Ceftriaxone Sodium · Injection
Last checked: Nov 19, 2026Latest source record: Jan 13, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2005
Apr 20, 2005
Approved uses
1
Original approval plus efficacy supplements
Registered trials
218
68 Phase 3, 21 recruiting
FAERS reports
33,350
31,411 serious, 5,724 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 13, 2022.
Ceftriaxone for Injection and Dextrose Injection is indicated for the treatment of the following infections when caused by susceptible bacteria. Ceftriaxone for Injection and Dextrose Injection is a cephalosporin antibacterial indicated for the treatment of the following infections caused by susceptible isolates of the designated bacteria: Lower Respiratory Tract Infections ( 1.1 ); Skin and Skin Structure Infections ( 1.2 ); Complicated and Uncomplicated Urinary Tract Infections ( 1.3 ); Pelvic Inflammatory Disease ( 1.4 ); Bacterial Septicemia ( 1.5 ); Bone and Joint Infections ( 1.6 ); Intra-abdominal Infections ( 1.7 ); Meningitis ( 1.8 ); and Surgical Prophylaxis ( 1.9 ). To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ceftriaxone for Injection and Dextrose Injection and other antibacterial drugs, Ceftriaxone for Injection and Dextrose Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.10 ) 1.1 Lower Respiratory Tract Infections Lower respiratory tract infections caused by Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis or Serratia marcescens . 1.2 Skin and Skin Structure Infections Skin and skin structure infections caused by Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Viridans group streptococci, Escherichia coli, Enterobacter cloacae, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, Morganella morganii The efficacy for these organisms in this organ system were studied in fewer than ten infections. , Pseudomonas aeruginosa, Serratia marcescens, Acinetobacter...
Mechanism: Ceftriaxone is an antibacterial drug [see Microbiology (12.4) ].
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
2 products under this application
- CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER · CEFTRIAXONE SODIUM EQ 1GM BASE/VIAL · INJECTABLE, INJECTION · Prescription · TE AP
- CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER · CEFTRIAXONE SODIUM EQ 2GM BASE/VIAL · INJECTABLE, INJECTION · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Ceftriaxone" as an intervention, any sponsor and status, largest first.
- Selective Decontamination of the Digestive Tract in Intensive Care Unit PatientsPivotal-lookingCompleted
The George InstituteAcademic, hospital or other
NCT02389036 · 20,010 participants · Start May 1, 2017 · Primary completion Apr 26, 2023
Drug: SDD Oral Paste; SDD Gastric Suspension and 1 more · For: Critical Illness; Sepsis; Septic Shock and 1 more
Sites: Sydney, Australia; Toronto, Canada; London, United Kingdom
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaPivotal-lookingRecruiting
UMC UtrechtAcademic, hospital or other
NCT02735707 · 20,000 participants (planned) · Start Apr 11, 2016 · Primary completion Jun 2028
Drug: Ceftriaxone + Macrolide; Moxifloxacin or Levofloxacin and 47 more · For: Respiratory Tract Diseases; Influenza (Pandemic); Influenza and 7 more
Sites: Jacksonville, Florida; Augusta, Georgia; Chicago, Illinois · 408 sites in all
- A Study to Compare Different Antibiotics and Different Modes of Fluid Treatment for Children With Severe PneumoniaPivotal-lookingCompleted
University of OxfordAcademic, hospital or other
NCT04041791 · 4,392 participants · Start Aug 19, 2019 · Primary completion Apr 5, 2024
Drug: Benzyl penicillin; Gentamicin Sulfate and 3 more · For: Pneumonia
Sites: Machakos, Kenya
- PRophylaxis Against Early VENTilator-associated Infections in Acute Brain InjuryPivotal-lookingRecruiting
The George InstituteAcademic, hospital or other
NCT06819592 · 3,300 participants (planned) · Start Oct 30, 2025 · Primary completion Aug 2029
Drug: Ceftriaxone 2g diluted in >200ml 0.9%sodium chloride; Placebo comparator - no ceftriaxone · For: All-cause Mortality; Quality of Life; Disability, Intellectual and 4 more
Sites: Canberra, Australia; Camperdown, Australia; Darlinghurst, Australia · 29 sites in all
- Prehospital Antibiotics Against Sepsis TrialPivotal-lookingCompleted
Amsterdam UMC, location VUmcAcademic, hospital or other
NCT01988428 · 2,672 participants · Start Jun 2014 · Primary completion Jun 2017
Drug: Ceftriaxone 2000 mg · For: Sepsis; Severe Sepsis; Septic Shock
Sites: Amstelveen, Netherlands; Amersfoort, Netherlands; Amsterdam, Netherlands · 34 sites in all
- Paramedic Initiated Treatment of Sepsis Targeting Out-of-hospital Patients (PITSTOP)Pivotal-lookingCompleted
Dr. Damon ScalesAcademic, hospital or other
NCT03068741 · 2,061 participants · Start Mar 23, 2020 · Primary completion Nov 17, 2025
Drug: Comparison 1: Prehospital Ceftriaxone; Comparison 1: Placebo and 2 more · For: Severe Sepsis or Septic Shock
Sites: Toronto, Canada · 4 sites in all
- First Line Antimicrobials in Children With Complicated Severe Acute MalnutritionPivotal-lookingStatus unknown
University of OxfordAcademic, hospital or other
NCT03174236 · 2,000 participants (planned) · Start Sep 4, 2017 · Primary completion Jan 31, 2020
Drug: Ceftriaxone; Benzyl penicillin and 2 more · For: Malnutrition Severe; Antibiotic Resistance; Antibiotic Toxicity
Sites: Kilifi, Kenya; Mombasa, Kenya; Nairobi, Kenya · 8 sites in all
- AUTOP 2: Screen-and-treat Strategy for Vaginal Flora Abnormalities by Molecular Biology in Pregnant Women at High Risk of Preterm BirthPivotal-lookingNot yet recruiting
Assistance Publique Hopitaux De MarseilleAcademic, hospital or other
NCT06349122 · 1,794 participants (planned) · Start Oct 2026 · Primary completion Jun 2029
Drug: Azithromycin; Ceftriaxone and 3 more · For: Bacterial Vaginosis; Vaginal Dysbiosis; Premature Delivery
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use3,609
- drug ineffective3,316
- pyrexia1,775
- acute kidney injury1,662
- condition aggravated1,427
- dyspnoea1,143
- pneumonia1,101
- drug interaction1,057
- vomiting1,039
- nausea996
- drug reaction with eosinophilia and systemic symptoms940
- diarrhoea921
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 136 |
| 2005 | 226 |
| 2006 | 237 |
| 2007 | 252 |
| 2008 | 360 |
| 2009 | 411 |
| 2010 | 375 |
| 2011 | 507 |
| 2012 | 698 |
| 2013 | 790 |
| 2014 | 1,024 |
| 2015 | 969 |
| 2016 | 1,254 |
| 2017 | 1,422 |
| 2018 | 2,080 |
| 2019 | 2,192 |
| 2020 | 3,821 |
| 2021 | 3,621 |
| 2022 | 2,871 |
| 2023 | 2,637 |
| 2024 | 2,813 |
| 2025 | 2,709 |
| 2026 | 1,944 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial.
Harris PNA, Tambyah PA, Lye DC, et al. · JAMA 2018 · Comparative Study, Equivalence Trial
- Ceftriaxone to prevent early ventilator-associated pneumonia in patients with acute brain injury: a multicentre, randomised, double-blind, placebo-controlled, assessor-masked superiority trial.
Dahyot-Fizelier C, Lasocki S, Kerforne T, et al. · Lancet Respir Med 2024 · Multicenter Study, Research Support, Non-U.S. Gov't
- Efficacy of Ceftriaxone 1 g daily Versus 2 g daily for The Treatment of Community-Acquired Pneumonia: A Systematic Review with Meta-Analysis.
Telles JP, Cieslinski J, Gasparetto J, et al. · Expert Rev Anti Infect Ther 2019 · Comparative Study, Meta-Analysis
- Efficacy and safety of first- and second-line antibiotics for cellulitis and erysipelas: a network meta-analysis of randomized controlled trials.
Shu Z, Cao J, Li H, et al. · Arch Dermatol Res 2024 · Systematic Review, Network Meta-Analysis
- Aztreonam for Neisseria gonorrhoeae: a systematic review and meta-analysis.
Barbee LA, Golden MR · J Antimicrob Chemother 2020 · Meta-Analysis, Research Support, N.I.H., Extramural
- Manifestations, complications, and treatment of neurobrucellosis: a systematic review and meta-analysis.
Tajerian A, Sofian M, Zarinfar N, et al. · Int J Neurosci 2024 · Meta-Analysis, Systematic Review
Sponsor: B Braun
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.